Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATHA 
Athira Pharma Inc (ATHA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: ATHA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 47.89% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.54M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 3 | Beta 2.97 | 52 Weeks Range 2.20 - 7.04 | Updated Date 11/13/2025 |
52 Weeks Range 2.20 - 7.04 | Updated Date 11/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.67 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.13 | Actual -1.68 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -37.78% | Return on Equity (TTM) -89.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -6073523 | Price to Sales(TTM) - |
Enterprise Value -6073523 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.31 | Shares Outstanding 3943887 | Shares Floating 2568496 |
Shares Outstanding 3943887 | Shares Floating 2568496 | ||
Percent Insiders 7.73 | Percent Institutions 44.13 |
Upturn AI SWOT
Athira Pharma Inc
Company Overview
History and Background
Athira Pharma, Inc. (ATHA) is a clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal health and slow neurodegeneration. Founded in 2011, the company's initial focus was on developing therapies for Alzheimer's disease and other neurodegenerative conditions.
Core Business Areas
- Neurodegenerative Disease Therapies: Focuses on developing disease-modifying therapies for Alzheimer's and Parkinson's. Athira's pipeline includes fosgonimeton, a small molecule designed to enhance the HGF/MET pathway, promoting neuroprotection and improving synaptic function.
Leadership and Structure
Athira Pharma's leadership team includes Mark Litton, PhD, President and CEO. The company has a board of directors and operates with a focus on research and development of its pipeline.
Top Products and Market Share
Key Offerings
- Fosgonimeton: Fosgonimeton is Athira's lead product candidate, a small molecule designed to enhance the HGF/MET pathway for the treatment of Alzheimer's disease and Parkinson's disease. It's currently in Phase 2 clinical trials. Market share data for potential Alzheimer's treatments is complex due to competition from Eisai/Biogen's Leqembi (market share in early stages post-approval) and other ongoing research. Competitors: Eisai/Biogen, Eli Lilly, Roche.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurodegenerative diseases is highly competitive and rapidly evolving. There's a significant unmet medical need for effective treatments for Alzheimer's and Parkinson's disease.
Positioning
Athira is positioned as a company developing a novel approach to treating neurodegenerative diseases by enhancing the HGF/MET pathway. This approach aims to improve neuronal health and synaptic function.
Total Addressable Market (TAM)
The global Alzheimer's disease market is expected to reach hundreds of billions of dollars. Athira is positioned to capture a portion of this market with its potential disease-modifying therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting the HGF/MET pathway
- Lead product candidate in Phase 2 clinical trials
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited revenue and reliance on funding
- Clinical trial risks and regulatory hurdles
- High competition in the neurodegenerative disease market
- History of management turnover
Opportunities
- Positive clinical trial results for fosgonimeton
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Increasing prevalence of Alzheimer's disease
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- ROCHE.SW
Competitive Landscape
Athira faces significant competition from large pharmaceutical companies with established research and development programs. Athira's advantage lies in its novel therapeutic approach, but it needs to demonstrate clinical efficacy to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Athira's historical growth is measured by its progress in clinical trials and the development of its pipeline.
Future Projections: Future growth depends on the success of fosgonimeton and other pipeline candidates in clinical trials and regulatory approval.
Recent Initiatives: Recent initiatives include advancing clinical trials for fosgonimeton and exploring potential partnerships.
Summary
Athira Pharma is a clinical-stage biopharmaceutical company with a novel approach to treating neurodegenerative diseases. Its success hinges on the positive outcome of its fosgonimeton clinical trials. The company faces substantial risks common to its stage, including securing funding and navigating regulatory hurdles. A major need to watch out for would be clinical trials failing, as they have no revenue to operate on.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company website
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share information are based on available estimates and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Athira Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2020-09-18 | President, CEO & Director Dr. Mark J. Litton M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.athira.com |
Full time employees 26 | Website https://www.athira.com | ||
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.